Back to News
May 19, 2026 8:00 PM

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA) ("Aura" or the "Company"), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, "Inducement Awards") were granted to Natalie Holles, Aura's new Chief Executive Officer and President, on May 19, 2026 (the "Grant Date"). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles' offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Awards consist of (i) non-qualified stock options to purchase an aggregate of 2,169,103 shares of the Company's common stock ("Common Stock") with an exercise price of $7.39 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date (the "Option Award"), (ii) ...